A pilot trial of the daily intraperitoneal administration of recombinant interleukin-2

M. Markman, N. Iannotti, T. Hakes, B. Reichman, S. Rubin, W. Jones, W. Hoskins, J. L. Lewis

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

In an effort to develop a rational and practical intraperitoneal (i.p.) recombinant interleukin-2 (rIL-2) program that could be explored in future studies of combination i.p. biological therapy, a pilot trial of single-agent rIL-2 delivered i.p. as a single daily dose on a 5-times-weekly schedule was initiated. With a daily x 5 dose of 8 x 105 units/m2 rIL-2 (Ro 23-6019) only minimal systemic and local toxicity was encountered. This dose is recommended for future trials of combination i.p. biological therapy employing a daily x 5 schedule.

Original languageEnglish
Pages (from-to)44-46
Number of pages3
JournalRegional Cancer Treatment
Volume3
Issue number1
StatePublished - 1990

Fingerprint

Dive into the research topics of 'A pilot trial of the daily intraperitoneal administration of recombinant interleukin-2'. Together they form a unique fingerprint.

Cite this